ImmunoVaccine Technologies Inc.
$636,596.00 CAD
≈ 8 Canadians' average pay for a year
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- April 1, 2020 – December 31, 2020
- Reference
- nrc-cnrc:172-2020-2021-Q1-948901
Published purpose
This project aims to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company’s DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. IMV believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions